サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1571364

臨床試験市場規模・予測、世界・地域別シェア、動向、成長機会分析レポート：試験デザイン、適応症、フェーズ、地域別

Clinical Trials Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Study Design, Indications, Phase Type, and Geography

出版日
ページ情報
英文 211 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
臨床試験市場規模・予測、世界・地域別シェア、動向、成長機会分析レポート：試験デザイン、適応症、フェーズ、地域別
出版日: 2024年09月20日
発行: The Insight Partners
ページ情報: 英文 211 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

臨床試験市場は、2023年の433億7,000万米ドルから成長し、2031年には733億3,000万米ドルに達すると予測されており、2023～2031年のCAGRは6.8%と予測されています。臨床試験数の大幅な増加に伴う臨床試験のアウトソーシングの実践と、研究開発活動の急増に伴う製薬業界の繁栄が、臨床試験市場の成長に寄与しています。しかし、臨床試験には費用と時間がかかるため、市場成長の妨げとなっています。さらに、AIを活用した臨床試験は、今後数年間で新たな臨床試験市場の動向をもたらすと予想されます。

臨床試験とは、医学的、外科的、または行動学的介入を人々を対象に試験する調査研究です。これらの臨床試験は、新薬、食事療法、医療機器（例えばペースメーカー）などの新しい治療や予防が、人々にとって安全で効果的かどうかを研究者が判断する1次調査です。多くの場合、臨床試験は、新しい治療が既存の治療よりも効果的であるか、あるいは有害な副作用が少ないかどうかを知るために行われます。

2023年の世界臨床試験市場では、北米が大きなシェアを占めています。北米の臨床試験市場は、米国、カナダ、メキシコに区分されます。米国は主要な臨床研究先となっています。臨床試験の半数近くが米国で実施されています。さらに、確立された医療インフラ、迅速な承認スケジュール、有利な規制枠組み、世界的に認められた臨床試験生成データなどの理由から、ほとんどの製薬研究会社は米国での臨床試験実施を好んでいます。世界保健機関（WHO）の報告書によると、米国の臨床試験件数は最も多く、2021年には15万7618件に上った。

米国における臨床試験市場の成長は、臨床試験に応用するために企業が発売した革新的な製品に起因しています。臨床試験のための様々なサービスを提供する臨床研究機関（CRO）であるメディカル・メトリックスは、"Assessa "を提供しています。この製品は創薬や関連臨床試験の意思決定プロセスを支援します。認知症、認知機能障害、アルツハイマー病、パーキンソン病、統合失調症、その他の記憶関連疾患などの神経疾患に対する薬剤の発見を支援します。米国では臨床試験の件数が増加しており、同国の臨床試験市場の成長に有利です。

分散型臨床試験とハイブリッド型臨床試験の採用が今後の市場機会をもたらす

分散型臨床試験（DCT）に登録された被験者は、病院内の臨床試験実施施設に頻繁にアクセスする必要がないです。DCTでは、臨床研究のための患者へのアクセス、遠隔データ収集とモニタリング、治験責任医師と被験者間のコミュニケーションを可能にするためにデジタル技術が使用されます。ハイブリッド臨床試験のアプローチは、在宅と現場での活動を組み合わせることで、最高の患者体験をもたらし、複雑なプロトコールレジメニーを満たし、様々な治療領域や臨床試験フェーズのジャーニーで支持を集めています。当初、DCTの採用は、患者のプライバシー、データセキュリティ、規制上の障壁、複雑なプロトコール制度などの課題によって影響を受けた。しかし、COVID-19の大流行は、この健康危機の中で対面試験が実行不可能であったため、臨床試験のスポンサーに医薬品開発のための分散型ハイブリッド臨床技術の採用を強いることとなった。通勤に制限が課される中、データを収集し、臨床試験を継続する唯一の方法は、遠隔地で作業し、プロセスを加速するためにテクノロジーを最適に活用することだった。マッキンゼーが提供したデータによると、臨床試験の潜在的参加者の～70％が試験実施施設から離れています。従って、分散化によって治験へのアクセスが広がり、より多くの被験者、潜在的により多様な患者プールに到達することができます。

ハイブリッド臨床試験により、スポンサーは試験デザインにDCT要素を戦略的に組み込むことができます。このような試験モデルはこれまでにない柔軟性を提供するため、より多くの企業がハイブリッド試験に関心を示しており、業界情勢を再定義しつつあります。ObvioHealthによると、FDAは今後の臨床研究の信頼性を高めるため、2023年にDCT法の使用をサポートするプロトコルを発表する計画を持っていました。このように、従来の臨床試験手法よりも分散型臨床試験やハイブリッド臨床試験の利用に注目が集まっていることから、予測期間中に臨床試験市場に有利な機会がもたらされると期待されています。

試験デザインに基づく洞察

試験デザイン別に、市場は介入試験と拡大アクセス試験に二分されます。

適応症に基づく洞察

適応症別に、市場は心血管疾患、がん、神経疾患、自己免疫疾患/炎症、疼痛管理、糖尿病、肥満、代謝性疾患、その他に区分されます。

フェーズに基づく洞察

フェーズ別に、臨床試験市場はフェーズI、フェーズII、フェーズIIIに分けられます。

臨床試験市場競合情勢と主な発展

IQVIA Holdings Inc、Parexel International Corporation、IXICO Plc、Charles River Laboratories Inc、ICON Plc、WuXi AppTec Co Ltd、SGS SA、Syneos Health Inc、SIRO Clinpharm Private Limited、Thermo Fisher Scientific Inc、Laboratory Corp of America Holdings、CliniRx、Caidya、Oracle Corp、Medpaceなどが臨床試験市場で事業を展開する主要企業です。

米国食品医薬品局、米国疾病管理予防センター（CDC）、世界疾病負担調査は、臨床試験市場レポート作成時に参照した一次情報および二次情報の一つです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 2次調査
  • 1次調査
    • 仮説の策定
    • マクロ経済要因分析
    • 基礎数値の作成
    • データの三角測量
    • 国レベルのデータ

第4章 臨床試験市場の情勢

  • PEST分析

第5章 臨床試験市場-主な市場力学

  • 臨床試験市場- 主な市場力学
  • 市場促進要因
    • 臨床試験数の急増に伴う臨床試験のアウトソーシング化
    • 研究開発活動の急増に伴う製薬業界の繁栄
  • 市場抑制要因
    • 高価で時間のかかるプロセス
  • 市場機会
    • 分散型臨床試験とハイブリッド臨床試験の採用
  • 今後の動向
    • AI主導型臨床試験
  • 促進要因と抑制要因の影響

第6章 臨床試験市場- 世界市場分析

  • 臨床試験市場の収益、2021年～2031年
  • 世界の臨床試験市場予測分析

第7章 臨床試験市場：試験デザイン別

  • 介入試験
  • 拡張アクセス試験

第8章 臨床試験市場：適応症別

  • 自己免疫疾患/炎症
  • 疼痛管理
  • 腫瘍疾患
  • 神経疾患
  • 糖尿病
  • 肥満症
  • 代謝疾患
  • 心血管疾患
  • その他

第9章 臨床試験市場：フェーズ別

  • フェーズI
  • フェーズII
  • フェーズIII

第10章 臨床試験市場：地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • ポーランド
    • スイス
    • スウェーデン
    • デンマーク
    • ベルギー
    • オランダ
    • その他欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • インドネシア
    • マレーシア
    • シンガポール
    • アジア太平洋地域のその他諸国
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • その他中東とアフリカ
  • 中南米
    • ブラジル
    • アルゼンチン
    • その他中南米

第11章 業界情勢

  • 臨床試験市場における成長戦略
  • 有機的成長戦略
  • 無機的成長戦略

第12章 企業プロファイル

  • QVIA Holdings Inc
  • Parexel International Corp
  • IXICO Plc
  • Charles River Laboratories International Inc
  • ICON Plc
  • WuXi AppTec Co Ltd
  • SGS SA
  • Syneos Health Inc
  • SIRO Clinpharm Pvt Ltd
  • Thermo Fisher Scientific Inc
  • Laboratory Corp of America Holdings
  • CliniRx Research Private Limited
  • Caidya
  • Oracle Corp
  • Medpace Holdings Inc

第13章 付録

図表

List Of Tables

  • Table 1. Clinical Trials Market Segmentation
  • Table 2. R&D Investments by Major Pharmaceutical Companies
  • Table 3. North America: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 4. North America: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 5. North America: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 6. United States: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 7. United States: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 8. United States: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 9. Canada: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 10. Canada: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 11. Canada: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 12. Mexico: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 13. Mexico: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 14. Mexico: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 15. Europe: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 16. Europe: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 17. Europe: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 18. United Kingdom: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 19. United Kingdom: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 20. United Kingdom: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 21. Germany: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 22. Germany: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 23. Germany: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 24. France: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 25. France: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 26. France: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 27. Spain: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 28. Spain: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 29. Spain: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 30. Italy: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 31. Italy: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 32. Italy: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 33. Poland: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 34. Poland: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 35. Poland: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 36. Switzerland: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 37. Switzerland: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 38. Switzerland: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 39. Sweden: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 40. Sweden: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 41. Sweden: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 42. Denmark: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 43. Denmark: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 44. Denmark: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 45. Belgium: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 46. Belgium: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 47. Belgium: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 48. Netherlands: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 49. Netherlands: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 50. Netherlands: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 51. Rest of Europe: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 52. Rest of Europe: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 53. Rest of Europe: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 54. Asia Pacific: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 55. Asia Pacific: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 56. Asia Pacific: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 57. China: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 58. China: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 59. China: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 60. Japan: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 61. Japan: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 62. Japan: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 63. India: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 64. India: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 65. India: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 66. Australia: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 67. Australia: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 68. Australia: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 69. South Korea: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 70. South Korea: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 71. South Korea: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 72. Indonesia: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 73. Indonesia: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 74. Indonesia: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 75. Malaysia: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 76. Malaysia: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 77. Malaysia: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 78. Singapore: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 79. Singapore: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 80. Singapore: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 81. Rest of APAC: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 82. Rest of APAC: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 83. Rest of APAC: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 84. Middle East and Africa: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 85. Middle East and Africa: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 86. Middle East and Africa: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 87. Saudi Arabia: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 88. Saudi Arabia: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 89. Saudi Arabia: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 90. South Africa: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 91. South Africa: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 92. South Africa: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 93. United Arab Emirates: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 94. United Arab Emirates: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 95. United Arab Emirates: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 96. Rest of Middle East and Africa: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 97. Rest of Middle East and Africa: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 98. Rest of Middle East and Africa: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 99. South and Central America: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 100. South and Central America: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 101. South and Central America: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 102. Brazil: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 103. Brazil: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 104. Brazil: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 105. Argentina: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 106. Argentina: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 107. Argentina: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 108. Rest of South and Central America: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Study Design
  • Table 109. Rest of South and Central America: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Indications
  • Table 110. Rest of South and Central America: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million) - by Phase
  • Table 111. Recent Organic Growth Strategies in Clinical Trials Market
  • Table 112. Recent Inorganic Growth Strategies in the Clinical Trials Market
  • Table 113. Glossary of Terms, Clinical Trials Market

List Of Figures

  • Figure 1. Clinical Trials Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Clinical Trials Market Revenue (US$ Million), 2021-2031
  • Figure 5. Clinical Trials Market Share (%) - by Study Design (2023 and 2031)
  • Figure 6. Interventional Trials: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Expanded Access Trials: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Clinical Trials Market Share (%) - by Indications (2023 and 2031)
  • Figure 9. Autoimmune Diseases/Inflammation : Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Pain Management: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Oncological Conditions: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Neurological Disorders: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Diabetes: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Obesity: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Metabolic Disorders: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Cardiovascular Diseases: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Others: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Clinical Trials Market Share (%) - by Phase (2023 and 2031)
  • Figure 19. Phase I: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Phase II: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Phase III: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Clinical Trials Market Breakdown by Region, 2023 and 2031 (%)
  • Figure 23. North America: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 24. North America: Clinical Trials Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 25. United States: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 26. Canada: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 27. Mexico: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 28. Europe: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 29. Europe: Clinical Trials Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 30. United Kingdom: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 31. Germany: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 32. France: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 33. Spain: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 34. Italy: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 35. Poland: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 36. Switzerland: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 37. Sweden: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 38. Denmark: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 39. Belgium: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 40. Netherlands: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 41. Rest of Europe: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 42. Asia Pacific: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 43. Asia Pacific: Clinical Trials Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 44. China: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 45. Japan: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 46. India: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 47. Australia: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 48. South Korea: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 49. Indonesia: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 50. Malaysia: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 51. Singapore: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 52. Rest of APAC: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 53. Middle East and Africa: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 54. Middle East and Africa: Clinical Trials Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 55. Saudi Arabia: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 56. South Africa: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 57. United Arab Emirates: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 58. Rest of Middle East and Africa: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 59. South and Central America: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 60. South and Central America: Clinical Trials Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 61. Brazil: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 62. Argentina: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 63. Rest of South and Central America: Clinical Trials Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 64. Growth Strategies in Clinical Trials Market
目次
Product Code: TIPRE00006203

The clinical trials market is anticipated to grow from US$ 43.37 billion in 2023 and is projected to reach US$ 73.33 billion by 2031; it is expected to register a CAGR of 6.8% during 2023-2031. The practice of outsourcing clinical studies with a massive rise in the number of trials and the flourishing pharmaceutical industry with a surge in R&D activities are contributing to the clinical trials market growth. However, the expensive and time-consuming nature of trials hampers market growth. Further, AI-driven clinical trials are expected to bring new clinical trials market trends in the coming years.

Clinical trials are research studies that test a medical, surgical, or behavioral intervention in people. These trials are the primary way that researchers determine if a new form of treatment or prevention, such as a new drug, diet, or medical device (for example, a pacemaker), is safe and effective in people. Often, a clinical trial is designed to learn if a new treatment is more effective or has less harmful side effects than existing treatments.

North America accounted for a major share of the global clinical trials market in 2023. The clinical trials market in North America is segmented into the US, Canada, and Mexico. The US has become a leading clinical research destination. Nearly half of the clinical trials are conducted in the US. Additionally, most pharmaceutical research companies prefer to conduct clinical trials in the US due to established medical infrastructure, rapid approval timelines, a favorable regulatory framework, and accepted clinical trial-generated data globally. A World Health Organization (WHO) report states that the US had the highest number of clinical trials, with 157,618 trials in 2021.

The growth of the clinical trials market in the US can be attributed to innovative products launched by companies for applications in clinical trials. Medical Metrics, a clinical research organization (CRO) providing various services for clinical trials, offers "Assessa." This product assists in the decision-making process of drug discovery and related clinical studies. It helps discover drugs for neurological disorders, such as dementia, cognitive impairment, Alzheimer's disease, Parkinson's Disease, Schizophrenia, and other memory-related diseases. The rising number of clinical trials in the US favors the growth of the clinical trials market in the country.

Adoption of Decentralized Clinical Trials and Hybrid Clinical Trials to Provide Market Opportunities in Future

Subjects enrolled in decentralized clinical trials (DCT) do not need to access hospital-based trial sites frequently. In DCTs, digital technologies are used to enable access of patients for clinical research, remote data collection and monitoring, and communication between investigators and participants. A hybrid clinical trial approach combines home-based and on-site activities, bringing the best patient experience and meeting complex protocol regimes, gaining traction across various therapeutic areas and trial phase journeys. Initially, the adoption of DCT was affected due to challenges such as patient privacy, data security, regulatory barriers, and complex protocol regimes. However, the COVID-19 pandemic compelled the sponsors of clinical trials to adopt decentralized and hybrid clinical techniques for developing drugs, as in-person studies were not feasible amid this health crisis. With restrictions imposed on commute, the only way to gather data and keep trials going was to work remotely and make optimal use of technologies to accelerate processes. According to the data provided by McKinsey, ~70% of the potential participants for clinical trials stay away from trial sites. Therefore, decentralization broadens trial access to reach a larger number of subjects, consisting of potentially a more diverse pool of patients.

Hybrid clinical trials allow sponsors to strategically incorporate DCT elements into study designs. These trial models offer unprecedented flexibility; thus, more companies are showing interest in hybrid trials, which is redefining the industry landscape. According to ObvioHealth, the FDA had plans to unveil protocols to support the use of DCT methods in 2023 to enhance the credibility of future clinical research. Thus, the increasing focus on using decentralized and hybrid clinical trials over traditional clinical trial methods is expected to provide lucrative opportunities for the clinical trials market during the forecast period.

Study Design -Based Insights

Based on study design, the market is bifurcated into interventional trials and expanded access trials.

Indication -Based Insights

By indication, the market is segmented into cardiovascular diseases, oncological conditions, neurological disorders, autoimmune diseases/inflammation, pain management, diabetes, obesity, metabolic disorders, and others.

Phase -Based Insights

Based on phase, the clinical trials market is divided into Phase I, Phase II, and Phase III.

Clinical Trials Market: Competitive Landscape and Key Developments

IQVIA Holdings Inc, Parexel International Corporation, IXICO Plc, Charles River Laboratories Inc, ICON Plc, WuXi AppTec Co Ltd, SGS SA, Syneos Health Inc, SIRO Clinpharm Private Limited, Thermo Fisher Scientific Inc, Laboratory Corp of America Holdings, CliniRx, Caidya, Oracle Corp, and Medpace are among the key companies operating in the clinical trials market.

The US Food and Drug Administration, Centers for Disease Control and Prevention (CDC), and Global Burden of Disease Study are among the primary and secondary sources referred to while preparing the clinical trials market report.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Clinical Trials Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Clinical Trials Market - Key Market Dynamics

  • 5.1 Clinical Trials Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Practice of Outsourcing Clinical Studies with Massive Rise in Number of Trials
    • 5.2.2 Flourishing Pharmaceutical Industry with Surge in R&D Activities
  • 5.3 Market Restraints
    • 5.3.1 Expensive and Time-Consuming Process
  • 5.4 Market Opportunities
    • 5.4.1 Adoption of Decentralized Clinical Trials and Hybrid Clinical Trials
  • 5.5 Future Trends
    • 5.5.1 AI-Driven Clinical Trials
  • 5.6 Impact of Drivers and Restraints:

6. Clinical Trials Market - Global Market Analysis

  • 6.1 Clinical Trials Market Revenue (US$ Million), 2021-2031
  • 6.2 Global Clinical Trials Market Forecast Analysis

7. Clinical Trials Market Analysis - by Study Design

  • 7.1 Interventional Trials
    • 7.1.1 Overview
    • 7.1.2 Interventional Trials: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Expanded Access Trials
    • 7.2.1 Overview
    • 7.2.2 Expanded Access Trials: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)

8. Clinical Trials Market Analysis - by Indications

  • 8.1 Autoimmune Diseases/Inflammation
    • 8.1.1 Overview
    • 8.1.2 Autoimmune Diseases/Inflammation : Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Pain Management
    • 8.2.1 Overview
    • 8.2.2 Pain Management: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Oncological Conditions
    • 8.3.1 Overview
    • 8.3.2 Oncological Conditions: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Neurological Disorders
    • 8.4.1 Overview
    • 8.4.2 Neurological Disorders: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Diabetes
    • 8.5.1 Overview
    • 8.5.2 Diabetes: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Obesity
    • 8.6.1 Overview
    • 8.6.2 Obesity: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.7 Metabolic Disorders
    • 8.7.1 Overview
    • 8.7.2 Metabolic Disorders: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.8 Cardiovascular Diseases
    • 8.8.1 Overview
    • 8.8.2 Cardiovascular Diseases: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.9 Others
    • 8.9.1 Overview
    • 8.9.2 Others: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)

9. Clinical Trials Market Analysis - by Phase

  • 9.1 Phase I
    • 9.1.1 Overview
    • 9.1.2 Phase I: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Phase II
    • 9.2.1 Overview
    • 9.2.2 Phase II: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Phase III
    • 9.3.1 Overview
    • 9.3.2 Phase III: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)

10. Clinical Trials Market - Geographical Analysis

  • 10.1 Overview
  • 10.2 North America
    • 10.2.1 North America Clinical Trials Market Overview
    • 10.2.2 North America: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.2.2.1 North America: Clinical Trials Market - Revenue and Forecast Analysis - by Study Design
      • 10.2.2.2 North America: Clinical Trials Market - Revenue and Forecast Analysis - by Indications
      • 10.2.2.3 North America: Clinical Trials Market - Revenue and Forecast Analysis - by Phase
    • 10.2.3 North America: Clinical Trials Market - Revenue and Forecast Analysis - by Country
      • 10.2.3.1 United States: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.2.3.1.1 United States: Clinical Trials Market Breakdown, by Study Design
        • 10.2.3.1.2 United States: Clinical Trials Market Breakdown, by Indications
        • 10.2.3.1.3 United States: Clinical Trials Market Breakdown, by Phase
      • 10.2.3.2 Canada: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.2.3.2.1 Canada: Clinical Trials Market Breakdown, by Study Design
        • 10.2.3.2.2 Canada: Clinical Trials Market Breakdown, by Indications
        • 10.2.3.2.3 Canada: Clinical Trials Market Breakdown, by Phase
      • 10.2.3.3 Mexico: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.2.3.3.1 Mexico: Clinical Trials Market Breakdown, by Study Design
        • 10.2.3.3.2 Mexico: Clinical Trials Market Breakdown, by Indications
        • 10.2.3.3.3 Mexico: Clinical Trials Market Breakdown, by Phase
  • 10.3 Europe
    • 10.3.1 Europe Clinical Trials Market Overview
    • 10.3.2 Europe: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.3.2.1 Europe: Clinical Trials Market - Revenue and Forecast Analysis - by Study Design
      • 10.3.2.2 Europe: Clinical Trials Market - Revenue and Forecast Analysis - by Indications
      • 10.3.2.3 Europe: Clinical Trials Market - Revenue and Forecast Analysis - by Phase
    • 10.3.3 Europe: Clinical Trials Market - Revenue and Forecast Analysis - by Country
      • 10.3.3.1 United Kingdom: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.3.1.1 United Kingdom: Clinical Trials Market Breakdown, by Study Design
        • 10.3.3.1.2 United Kingdom: Clinical Trials Market Breakdown, by Indications
        • 10.3.3.1.3 United Kingdom: Clinical Trials Market Breakdown, by Phase
      • 10.3.3.2 Germany: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.3.2.1 Germany: Clinical Trials Market Breakdown, by Study Design
        • 10.3.3.2.2 Germany: Clinical Trials Market Breakdown, by Indications
        • 10.3.3.2.3 Germany: Clinical Trials Market Breakdown, by Phase
      • 10.3.3.3 France: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.3.3.1 France: Clinical Trials Market Breakdown, by Study Design
        • 10.3.3.3.2 France: Clinical Trials Market Breakdown, by Indications
        • 10.3.3.3.3 France: Clinical Trials Market Breakdown, by Phase
      • 10.3.3.4 Spain: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.3.4.1 Spain: Clinical Trials Market Breakdown, by Study Design
        • 10.3.3.4.2 Spain: Clinical Trials Market Breakdown, by Indications
        • 10.3.3.4.3 Spain: Clinical Trials Market Breakdown, by Phase
      • 10.3.3.5 Italy: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.3.5.1 Italy: Clinical Trials Market Breakdown, by Study Design
        • 10.3.3.5.2 Italy: Clinical Trials Market Breakdown, by Indications
        • 10.3.3.5.3 Italy: Clinical Trials Market Breakdown, by Phase
      • 10.3.3.6 Poland: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.3.6.1 Poland: Clinical Trials Market Breakdown, by Study Design
        • 10.3.3.6.2 Poland: Clinical Trials Market Breakdown, by Indications
        • 10.3.3.6.3 Poland: Clinical Trials Market Breakdown, by Phase
      • 10.3.3.7 Switzerland: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.3.7.1 Switzerland: Clinical Trials Market Breakdown, by Study Design
        • 10.3.3.7.2 Switzerland: Clinical Trials Market Breakdown, by Indications
        • 10.3.3.7.3 Switzerland: Clinical Trials Market Breakdown, by Phase
      • 10.3.3.8 Sweden: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.3.8.1 Sweden: Clinical Trials Market Breakdown, by Study Design
        • 10.3.3.8.2 Sweden: Clinical Trials Market Breakdown, by Indications
        • 10.3.3.8.3 Sweden: Clinical Trials Market Breakdown, by Phase
      • 10.3.3.9 Denmark: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.3.9.1 Denmark: Clinical Trials Market Breakdown, by Study Design
        • 10.3.3.9.2 Denmark: Clinical Trials Market Breakdown, by Indications
        • 10.3.3.9.3 Denmark: Clinical Trials Market Breakdown, by Phase
      • 10.3.3.10 Belgium: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.3.10.1 Belgium: Clinical Trials Market Breakdown, by Study Design
        • 10.3.3.10.2 Belgium: Clinical Trials Market Breakdown, by Indications
        • 10.3.3.10.3 Belgium: Clinical Trials Market Breakdown, by Phase
      • 10.3.3.11 Netherlands: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.3.11.1 Netherlands: Clinical Trials Market Breakdown, by Study Design
        • 10.3.3.11.2 Netherlands: Clinical Trials Market Breakdown, by Indications
        • 10.3.3.11.3 Netherlands: Clinical Trials Market Breakdown, by Phase
      • 10.3.3.12 Rest of Europe: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.3.3.12.1 Rest of Europe: Clinical Trials Market Breakdown, by Study Design
        • 10.3.3.12.2 Rest of Europe: Clinical Trials Market Breakdown, by Indications
        • 10.3.3.12.3 Rest of Europe: Clinical Trials Market Breakdown, by Phase
  • 10.4 Asia Pacific
    • 10.4.1 Asia Pacific Clinical Trials Market Overview
    • 10.4.2 Asia Pacific: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.4.2.1 Asia Pacific: Clinical Trials Market - Revenue and Forecast Analysis - by Study Design
      • 10.4.2.2 Asia Pacific: Clinical Trials Market - Revenue and Forecast Analysis - by Indications
      • 10.4.2.3 Asia Pacific: Clinical Trials Market - Revenue and Forecast Analysis - by Phase
    • 10.4.3 Asia Pacific: Clinical Trials Market - Revenue and Forecast Analysis - by Country
      • 10.4.3.1 China: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.4.3.1.1 China: Clinical Trials Market Breakdown, by Study Design
        • 10.4.3.1.2 China: Clinical Trials Market Breakdown, by Indications
        • 10.4.3.1.3 China: Clinical Trials Market Breakdown, by Phase
      • 10.4.3.2 Japan: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.4.3.2.1 Japan: Clinical Trials Market Breakdown, by Study Design
        • 10.4.3.2.2 Japan: Clinical Trials Market Breakdown, by Indications
        • 10.4.3.2.3 Japan: Clinical Trials Market Breakdown, by Phase
      • 10.4.3.3 India: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.4.3.3.1 India: Clinical Trials Market Breakdown, by Study Design
        • 10.4.3.3.2 India: Clinical Trials Market Breakdown, by Indications
        • 10.4.3.3.3 India: Clinical Trials Market Breakdown, by Phase
      • 10.4.3.4 Australia: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.4.3.4.1 Australia: Clinical Trials Market Breakdown, by Study Design
        • 10.4.3.4.2 Australia: Clinical Trials Market Breakdown, by Indications
        • 10.4.3.4.3 Australia: Clinical Trials Market Breakdown, by Phase
      • 10.4.3.5 South Korea: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.4.3.5.1 South Korea: Clinical Trials Market Breakdown, by Study Design
        • 10.4.3.5.2 South Korea: Clinical Trials Market Breakdown, by Indications
        • 10.4.3.5.3 South Korea: Clinical Trials Market Breakdown, by Phase
      • 10.4.3.6 Indonesia: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.4.3.6.1 Indonesia: Clinical Trials Market Breakdown, by Study Design
        • 10.4.3.6.2 Indonesia: Clinical Trials Market Breakdown, by Indications
        • 10.4.3.6.3 Indonesia: Clinical Trials Market Breakdown, by Phase
      • 10.4.3.7 Malaysia: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.4.3.7.1 Malaysia: Clinical Trials Market Breakdown, by Study Design
        • 10.4.3.7.2 Malaysia: Clinical Trials Market Breakdown, by Indications
        • 10.4.3.7.3 Malaysia: Clinical Trials Market Breakdown, by Phase
      • 10.4.3.8 Singapore: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.4.3.8.1 Singapore: Clinical Trials Market Breakdown, by Study Design
        • 10.4.3.8.2 Singapore: Clinical Trials Market Breakdown, by Indications
        • 10.4.3.8.3 Singapore: Clinical Trials Market Breakdown, by Phase
      • 10.4.3.9 Rest of APAC: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.4.3.9.1 Rest of APAC: Clinical Trials Market Breakdown, by Study Design
        • 10.4.3.9.2 Rest of APAC: Clinical Trials Market Breakdown, by Indications
        • 10.4.3.9.3 Rest of APAC: Clinical Trials Market Breakdown, by Phase
  • 10.5 Middle East and Africa
    • 10.5.1 Middle East and Africa Clinical Trials Market Overview
    • 10.5.2 Middle East and Africa: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.5.2.1 Middle East and Africa: Clinical Trials Market - Revenue and Forecast Analysis - by Study Design
      • 10.5.2.2 Middle East and Africa: Clinical Trials Market - Revenue and Forecast Analysis - by Indications
      • 10.5.2.3 Middle East and Africa: Clinical Trials Market - Revenue and Forecast Analysis - by Phase
    • 10.5.3 Middle East and Africa: Clinical Trials Market - Revenue and Forecast Analysis - by Country
      • 10.5.3.1 Saudi Arabia: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.5.3.1.1 Saudi Arabia: Clinical Trials Market Breakdown, by Study Design
        • 10.5.3.1.2 Saudi Arabia: Clinical Trials Market Breakdown, by Indications
        • 10.5.3.1.3 Saudi Arabia: Clinical Trials Market Breakdown, by Phase
      • 10.5.3.2 South Africa: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.5.3.2.1 South Africa: Clinical Trials Market Breakdown, by Study Design
        • 10.5.3.2.2 South Africa: Clinical Trials Market Breakdown, by Indications
        • 10.5.3.2.3 South Africa: Clinical Trials Market Breakdown, by Phase
      • 10.5.3.3 United Arab Emirates: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.5.3.3.1 United Arab Emirates: Clinical Trials Market Breakdown, by Study Design
        • 10.5.3.3.2 United Arab Emirates: Clinical Trials Market Breakdown, by Indications
        • 10.5.3.3.3 United Arab Emirates: Clinical Trials Market Breakdown, by Phase
      • 10.5.3.4 Rest of Middle East and Africa: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.5.3.4.1 Rest of Middle East and Africa: Clinical Trials Market Breakdown, by Study Design
        • 10.5.3.4.2 Rest of Middle East and Africa: Clinical Trials Market Breakdown, by Indications
        • 10.5.3.4.3 Rest of Middle East and Africa: Clinical Trials Market Breakdown, by Phase
  • 10.6 South and Central America
    • 10.6.1 South and Central America Clinical Trials Market Overview
    • 10.6.2 South and Central America: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
      • 10.6.2.1 South and Central America: Clinical Trials Market - Revenue and Forecast Analysis - by Study Design
      • 10.6.2.2 South and Central America: Clinical Trials Market - Revenue and Forecast Analysis - by Indications
      • 10.6.2.3 South and Central America: Clinical Trials Market - Revenue and Forecast Analysis - by Phase
    • 10.6.3 South and Central America: Clinical Trials Market - Revenue and Forecast Analysis - by Country
      • 10.6.3.1 Brazil: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.6.3.1.1 Brazil: Clinical Trials Market Breakdown, by Study Design
        • 10.6.3.1.2 Brazil: Clinical Trials Market Breakdown, by Indications
        • 10.6.3.1.3 Brazil: Clinical Trials Market Breakdown, by Phase
      • 10.6.3.2 Argentina: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.6.3.2.1 Argentina: Clinical Trials Market Breakdown, by Study Design
        • 10.6.3.2.2 Argentina: Clinical Trials Market Breakdown, by Indications
        • 10.6.3.2.3 Argentina: Clinical Trials Market Breakdown, by Phase
      • 10.6.3.3 Rest of South and Central America: Clinical Trials Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.6.3.3.1 Rest of South and Central America: Clinical Trials Market Breakdown, by Study Design
        • 10.6.3.3.2 Rest of South and Central America: Clinical Trials Market Breakdown, by Indications
        • 10.6.3.3.3 Rest of South and Central America: Clinical Trials Market Breakdown, by Phase

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in Clinical Trials Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 QVIA Holdings Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Parexel International Corp
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 IXICO Plc
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Charles River Laboratories International Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 ICON Plc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 WuXi AppTec Co Ltd
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 SGS SA
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Syneos Health Inc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 SIRO Clinpharm Pvt Ltd
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Thermo Fisher Scientific Inc
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments
  • 12.11 Laboratory Corp of America Holdings
    • 12.11.1 Key Facts
    • 12.11.2 Business Description
    • 12.11.3 Products and Services
    • 12.11.4 Financial Overview
    • 12.11.5 SWOT Analysis
    • 12.11.6 Key Developments
  • 12.12 CliniRx Research Private Limited
    • 12.12.1 Key Facts
    • 12.12.2 Business Description
    • 12.12.3 Products and Services
    • 12.12.4 Financial Overview
    • 12.12.5 SWOT Analysis
    • 12.12.6 Key Developments
  • 12.13 Caidya
    • 12.13.1 Key Facts
    • 12.13.2 Business Description
    • 12.13.3 Products and Services
    • 12.13.4 Financial Overview
    • 12.13.5 SWOT Analysis
    • 12.13.6 Key Developments
  • 12.14 Oracle Corp
    • 12.14.1 Key Facts
    • 12.14.2 Business Description
    • 12.14.3 Products and Services
    • 12.14.4 Financial Overview
    • 12.14.5 SWOT Analysis
    • 12.14.6 Key Developments
  • 12.15 Medpace Holdings Inc
    • 12.15.1 Key Facts
    • 12.15.2 Business Description
    • 12.15.3 Products and Services
    • 12.15.4 Financial Overview
    • 12.15.5 SWOT Analysis
    • 12.15.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms